Avalo Therapeutics (FRA:C6K0) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C6K0 Avalo Therapeutics Inc FRA:C6K0
42 GF Score
Price €16.66
GF Value €0.18
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Avalo Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

FRA:C6K0
42GF Score
Avalo Therapeutics Inc FRA:C6K0
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Avalo Therapeutics (FRA:C6K0) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of €16.66 is trading 9155.6% above its estimated GF Value™ of €0.18. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:C6K0:

  • FFO:
  • GF Value™: €0.18 vs. price of €16.66 (9155.6% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the FRA:C6K0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avalo Therapeutics Business Description

Other Exchanges AVTX:USAC6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
42GF Score

Get the complete analysis for FRA:C6K0

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.66
Price
€0.18
GF Value